Stockreport

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D [Yahoo! Finance]

SAB Biotherapeutics, Inc.  (SABS) 
PDF Study results support the chronic dosing of SAB-142 in an outpatient setting for the treatment of stage 3 autoimmune type 1 diabetes Phase 2b SAFEGUARD trial underway [Read more]